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Kim F. Michaelsen1, André Briend1,4, Henrik Friis1 and Pernille Kæstel1Abstract
Background: Children with severe acute malnutrition (SAM) have increased requirements for phosphorus and
magnesium during recovery. If requirements are not met, the children may develop refeeding hypophosphatemia
and hypomagnesemia. However, little is known about the effect of current therapeutic diets (F-75 and F-100) on
serum phosphate (S-phosphate) and magnesium (S-magnesium) in children with SAM.
Methods: Prospective observational study, with measurements of S-phosphate and S-magnesium at admission,
prior to rehabilitation phase and at discharge in children aged 6–59 months admitted with SAM to Jimma Hospital,
Ethiopia. Due to shortage of F-75, 25 (35 %) children were stabilized with diluted F-100 (75 kcal/100 ml).
Results: Of 72 children enrolled, the mean age was 32 ± 14 months, and edema was present in 50 (69 %). At
admission, mean S-phosphate was 0.92 ± 0.34 mmol/L, which was low compared to normal values, but increased to
1.38 ± 0.28 mmol/L at discharge, after on average 16 days. Mean S-magnesium, at admission, was 0.95 ± 0.23 mmol/L,
and increased to 1.13 ± 0.17 mmol/L at discharge. At discharge, 18 (51 %) children had S-phosphate below the normal
range, and 3 (9 %) had S-phosphate above. Most children (83 %) had S-magnesium above normal range for children.
Both S-phosphate and S-magnesium at admission were positively associated with serum albumin (S-albumin), but not
with anthropometric characteristics or co-diagnoses. Using diluted F-100 for stabilization was not associated with lower
S-phosphate or S-magnesium.
Conclusion: Hypophosphatemia was common among children with SAM at admission, and still subnormal in about
half of the children at discharge. This could be problematic for further recovery as phosphorus is needed for catch-up
growth and local diets are likely to be low in bioavailable phosphorus. The high S-magnesium levels at discharge does
not support that magnesium should be a limiting nutrient for growth in the F-100 diet. Although diluted F-100
(75 kcal/100 mL) is not designed for stabilizing children with SAM, it did not seem to cause lower S-phosphate than in
children fed F-75.
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Deficiencies of phosphorus, magnesium and other
minerals are common in children with severe acute mal-
nutrition (SAM) [1–5]. Refeeding with diets high in
carbohydrate but with inadequate amount of phosphorus
and magnesium can result in refeeding syndrome, char-
acterized by hypophosphatemia and hypomagnesemia,
sometimes resulting in respiratory or circulatory failure
or even death [6, 7]. Although concentrations of serum
phosphate (S-phosphate) and magnesium (S-magnesium)
may not adequately reflect body status, low levels may still
be suggestive of inadequate intake.
Treatment of children with SAM is divided in three
phases; stabilization, transition and rehabilitation. The aim
is first to stabilize the child and treat life-threatening com-
plications, and then to feed the child intensively to allow
for catch-up growth [8].
F-75 is formulated for the stabilization phase to be low
in protein, fat and sodium. F-100 or ready-to-use thera-
peutic food is given during transition and rehabilitation
phase and formulated to provide the nutrients needed
during catch up growth. Many nutritional rehabilitation
centers use commercial pre-mixed F-75 and F-100 prod-
ucts that simply need to be mixed with water, but F-75
and F-100 can also be made from locally available ingre-
dients with an added vitamin-mineral mix (including po-
tassium and magnesium but not phosphorus) [8].
When formulating these diets the phosphorus content
was not considered. The phosphorus content thus varies
from recipe to recipe depending on the ingredients used.
The main source of phosphorus in these diets is the pro-
tein source; thus the amount of phosphorus depends on
the amount and source of protein. The most widely used
recipes are based on skimmed milk powder. The World
Health Organization's (WHO) recipe for preparation of
F-75 and F-100 from locally available ingredients (see [8]
for more details) contain 2.5 g and 8.0 g of skimmed
milk powder per 100 mL of F-75 and F-100, respectively.
Assuming a phosphorus content of skimmed milk pow-
der of 956 mg/100 g [9] a child fed 130 mL of locally
prepared F-75 per kg per day during stabilization, gets
31 mg/kg/day of phosphorus and a child fed 200 mL/kg/
day of F-100 during rehabilitation, gets 152 mg/kg/day
of phosphorus.
Locally prepared F-75 thus provide limited amounts of
phosphorous during stabilization, and substantially less
than the 60 mg/kg/day recommended by WHO [8]. This
combination of a high proportion of energy from carbohy-
drate and the low phosphorus content may be problematic
[10]. Following new UN procurement specifications for F-
75 [11], extrinsic phosphorus, in the form of a phosphorus
salt has been added to the commercial pre-mixed F-75, to
a level of 56 mg of phosphorus per 100 mL of F-75 (i.e. a
child fed 130 mL of pre-mixed F-75 per kg per day, gets73 mg/kg/day of phosphorus). The bioavailability of the
phosphorus salt in children with SAM is unknown, but
might be low due to decreased gastric acidity, and it is not
clear if it is well absorbed [12–15]. Unlike phosphorus,
magnesium is included in the standard mineral mix, used
for local preparation of F-75, and both locally made and
pre-mixed F-75 and F-100 are thus fortified with magne-
sium [16]. However, as the total body magnesium deficit
might be greater than first anticipated, magnesium might
still be limiting for growth in the F-100 diet [17].
In some situations, when F-75 is not available, F-
100 is diluted to contain 75 kcal/100 ml, and used
for stabilization. However, the composition of F-75 is
quite different from diluted F-100 [18]. For instance,
in F-75 the amount of energy derived from carbohydrate
is much higher than in diluted F-100 (63 vs 41 E%). The
total amount of phosphorus supplied by pre-mixed F-75
(complying with UN procurement specification, i.e. 56 mg
of phosphorus per 100 mL) and diluted F-100, when feed-
ing a volume of 130 ml/kg/day is 73 and 57 mg/kg/day,
respectively.
To our knowledge, no other studies have evaluated the
effect of F-75 and F-100, complying with UN specifica-
tions, on S-phosphate and S-magnesium concentrations
during treatment of SAM.
We here present levels and predictors of S-phosphate
and S-magnesium in Ethiopian children with SAM,
treated according to current dietary regimen (i.e. including
a stabilization, transition and rehabilitation phase) using
F-75 and F-100 complying with UN specifications and in a
group of children stabilized with diluted F-100 (75 kcal/
100 mL) during a period of national shortage of F-75.
Methods
Study setting and participants
Children between 6 and 59 months of age admitted with
nutritional edema and/or severe wasting (weight-for-
height < 70 % of the median based upon the National
Center for Health Statistics (NCHS) reference or Mid-
upper-arm-circumference (MUAC) < 11.0 cm) were re-
cruited for the study at the Nutritional Rehabilitation
Unit (NRU) or critical ward of the pediatric unit of
Jimma University Specialised Hospital (JUSH). Both chil-
dren with complicated and uncomplicated SAM were
treated at the NRU. Patients in shock, with severe re-
spiratory difficulties or uncontrolled significant bleeding
from any site were not included. If the parent or guard-
ian gave consent, the child was examined and a blood
sample was collected within the first 24 h after the child
received the first feed.
Anthropometric and clinical assessments
Anthropometric and clinical assessments were done, and
blood samples were collected at admission, at start of
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measured to the nearest 5 g using an electronic pediatric
scale (Tanita BD 815 MA, Tokyo, Japan). Most children
were too weak to stand at admission and stature of all
children, regardless of age, was measured as recumbent
length to the nearest 0.5 cm using a length board (SECA
416, Hamburg, Germany). Standing height was mea-
sured to the nearest cm for children longer than 100 cm
(i.e. maximum length of the length board), using a stadi-
ometer (SECA 214, Hamburg, Germany). Anthropomet-
ric z-scores based on the 2006 WHO child growth
standard were calculated [19]. For calculation of weight-
for-height and height-for-age z-scores in children of
24 months and older, height estimates were obtained by
subtracting 0.7 cm from the recumbent length. Admis-
sion height or length was used for calculation of weight-
for-height and height-for-age z-scores for all time points.
MUAC was measured to the nearest 0.1 cm using an in-
sertion tape (SECA 212, Hamburg, Germany). Presence
of bilateral pitting edema was assessed by applying a
gentle pressure with the thumb for 3 to 5 s to the dorsal
surface of both feet and graded on a scale from 1 to 3,
corresponding to edema detected on feet, feet and legs
or including hands and face. The degree of edema at
admission was reclassified as either mild (grade 1 and 2)
or generalized edema (grade 3). Vital signs (axillary
temperature, respiratory rate and pulse rate) were re-
corded by trained study nurses at admission.
As timing of follow-up measurements was based on
the clinical improvement of the individual child, the
time span between measurements varied. Days spent in
the hospital were calculated for each child as well as
days spent in each of the phases.
Information on co-diagnoses was extracted from the
child’s clinical record.
Blood collection and laboratory analysis
Venous blood was collected in dry tubes (SST™ Tubes,
Becton Dickinson A/S) for separation of serum. Serum
was separated within an hour after collection and kept
at −80 °C for later analysis. Phosphate, magnesium and
albumin were measured in serum using the automated
Architect C4000 system (Abbott Diagnostics, USA). S-
phosphate was determined by the phosphomolybdate
method (Ref. no. 7D71, Abbott). The reference range,
provided by the laboratory, for children 0–2 years
was 1.45–2.10 mmol/L; and for 2–12 years: 1.45–
1.78 mmol/L. S-magnesium was measured by the xylidyl
blue method (Ref. no. MG531, Randox, UK). Interference
from calcium was prevented by incorporation of a calcium
chelating agent. The reference range, as provided by the
laboratory, for children 5 months to 6 years was 0.70–
0.95 mmol/L. Serum albumin (S-albumin) was measured
by the bromcresol green method (ref no: 7D53-20,Abbott). The reference range for children (4 days–
14 years) was 38–54 g/L according to the manufacturer.
The acute-phase protein alpha1-acid glycoprotein
(AGP) was measured in serum using the automated
Humastar 80 analyser (Human Diagnostics, Wiesbaden,
Germany) and analyzed using polyclonal rabbit anti-
human AGP antibody (code Q0326, DAKO Denmark
A/S, Glostrup, Denmark).
Potassium was measured in serum, but not reported
here as measurements are very sensitive to hemolysis.
Hemolysis was present to some degree (visual inspection)
in most samples and in particular in baseline samples,
most likely reflecting the difficulties in collecting blood at
this severe stage.
Treatment
Treatment was based on the Ethiopian guideline for the
management of children with SAM [20] and consisted
of a stabilization, transition and rehabilitation phase.
Therapeutic diets used in the NRU were the pre-mixed
F-75 and F-100 (Nutriset, Malaunay, France), containing
560 and 579 mg/L of phosphorus and 85 and 154 mg/L
of magnesium, respectively when mixed with water as
per manufacturer specifications. At admission the chil-
dren were given F-75 (100 kcal/kg/day). When appetite
returned and/or edema had started to resolve, F-75 was
replaced with an equal volume of F-100 (130 kcal/kg/
day). This marked the start of the transition phase. Once
the appetite was good and detectable edema had re-
solved the child was moved to the rehabilitation phase
where F-100 was given at full dose (200 kcal/kg/day).
During the first 3 months of 2012 there was a national
shortage of F-75 and all children admitted were stabi-
lized with diluted F-100 in place of F-75. F-100 was di-
luted to an energy density of 75 kcal/100 mL, by adding
2700 mL instead of 2000 mL of water to one sachet of
F-100 (456 g).
Ethics
The study was approved by the College of Public Health
and Medical Science ethical review board, Jimma
University (Ref. no. RPGC/229/2011 and RPGC/16/
2012). A consultative approval was obtained from the
Danish National Board of Research Ethics. All parents/
guardians gave oral and written consent to participate,
after receiving oral and written information about the
study and examinations, in local language. Parents/
guardians were informed that they could withdraw from
the study at any time without compromising the treat-
ment of their child. Study blood samples were analyzed
after completion of the study and results were not avail-
able to clinicians, and thus could not affect the treatment
given. All study participants received standard treat-
ment for their nutritional and additional co-morbidities
Table 1 Anthropometric, clinical and biochemistry data for 72
severely malnourished children at admission, by presence of
edemaa
Edema No edema P
(n = 50) (n = 22)
Female sex 24 (48.0) 8 (36.4) 0.36
Age, months 35 ± 14 26 ± 12 0.01
Anthropometric data
Weight-for-height, z −2.9 ± 1.6 −4.3 ± 0.9 <0.001
Height-for-age, z −3.0 ± 2.0 −3.9 ± 1.8 0.059
Mid-upper arm circumference, cm 11.6 ± 1.5 9.5 ± 0.9 <0.001
Clinical data
Axillary temperature, °C 36.3 ± 0.8 36.0 ± 0.6 0.11
Respiratory rate, breaths/min 32.1 ± 4.0 32.2 ± 3.3 0.91
Pulse rate, beats/min 113.4 ± 7.8 114.2 ± 6.6 0.68
Reported morbidity previous month
Fever 40 (80.0) 17 (77.3) 0.79
Malaria 15 (30.0) 6 (27.3) 0.82
Cough or difficult breathing 15 (30.0) 11 (50.0) 0.10
Diarrhea 43 (86.0) 19 (86.4) 0.97
Measles 5 (10.0) 0 (0.0) 0.12
Morbidity≥ 1 50 (100) 21 (95.5) 0.13
Co-diagnoses
HIV 0 (0.0) 2 (9.1) 0.03
Tuberculosis 0 (0.0) 3 (13.6) 0.01
Persistent diarrhea 2 (4.0) 0 (0.0) 0.34
Pneumonia 13 (26.0) 7 (31.8) 0.61
Co-diagnoses≥ 1 15 (30.0) 9 (40.9) 0.37
Biochemistry data
Serum albumin, g/L 13.6 ± 6.4 24.1 ± 8.4 <0.001
Serum alpha1-acid glycoprotein, g/L 2.9 ± 0.8 2.7 ± 1.0 0.39
a Values presented are mean ± SD or n (%). In 4 children no blood was
obtained at admission. 12 blood samples were not analyzed for
alpha1-acid glycoprotein
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ment guide, respectively.
Data handling and statistical analysis
Data was double entered using EpiData (version 3) and
analysed using Stata 12 (Stata/IC) (StataCorp LP, College
station, Texas, USA)).
Analysis of variance (ANOVA) was used to test for
differences in means and chi-square test to test for dif-
ferences in proportions between groups (i.e. children
with and without edema; children stabilized using F-75
and diluted F-100). Data on days spent in each phase
were transformed before analysis. As some children
were directly transferred from stabilization to rehabili-
tation phase (zero values) data were further trans-
formed prior to analysis by “log (1+ days in transition
phase)”.
Analysis of covariance was used to identify predictors
of baseline phosphate and magnesium while adjusting
for age and sex.
Change over time in S-phosphate and S-magnesium,
with adjustment for age, sex and edema, were ana-
lyzed using multilevel linear mixed-effects regression
model with child-specific random effects, as repeated
measurements per child were included in the analysis.
Fixed effects included diet fed during stabilization
phase (i.e. F-75 or diluted F-100) and treatment
phase. Models were checked by visual inspection of
standardized residual plots. Model estimates of mean
(95 % CI) S-phosphate and S-magnesium are pre-
sented in the figures. Post hoc comparison of the ef-
fects between children stabilized using F-75 and
diluted F-100 at different time points was performed
using linear combinations of coefficients via lincom
commands in STATA.
Results
From May 2011 to April 2012 a total of 200 children
aged 6–59 months were admitted with SAM; 37 children
were not eligible due to critical illness (mainly respira-
tory difficulties) and of 163 eligible children, guardians
of 72 (44 %) accepted the child’s participation in the
study. Children included in the study were older than
children not included (32 vs 26 months, P = 0.003), but
there were no differences in sex distribution and propor-
tion with edema.
Most children came from subsistence farming families
outside Jimma town. Edema was present in 50 (69 %) of
which 28 (56 %) had mild and 22 (44 %) generalized
edema. Anthropometric, clinical and biochemistry data
are presented in Table 1, separately for children with or
without edema.
Twenty-five (35 %) of the children were admitted during
a time period were there was a national shortage of F-75and were stabilized with diluted F-100 in place of F-75.
The 25 children fed diluted F-100 during stabilization did
not differ from those fed F-75 (results not shown) in sex,
age, proportion with edema, anthropometric measures
and reported morbidity. There was, however a higher
proportion diagnosed with pneumonia among those
that received F-75 (38 vs 8 %, P = 0.006).
Of the 72 children enrolled, 6 were not followed up (3
withdrew consent, 3 received ready-to-use therapeutic
foods). Of the remaining 66 children, 52 were followed
until discharge, 8 until self-discharge and 5 until time of
death (Fig. 1). Blood was collected and S-phosphate and
S-magnesium determined in 68 (94 %) children at ad-
mission, 51 (91 %) at start of rehabilitation phase and 35
(81 %) at discharge.
Fig. 1 Flow diagram of the study participants
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tion and rehabilitation phase was 6 (2–27), 2 (0–10) and
6 (1–22) days, respectively, and was not different
between children with and without edema or in children
fed diluted F-100 compared to those fed F-75 during
stabilization (data not shown).S-phosphate and S-magnesium at admission
At admission mean ± SD S-phosphate was 0.92 ±
0.34 mmol/L and 63 (93 %) children had values below the
age specific cut off defining normal values (<1.45 mmol/L).
Mean ± SD S-magnesium was 0.95 ± 0.23 mmol/L, 9 (13 %)
children had values below the age specific cut off defining
normal values (<0.70 mmol/L) and 33 (49 %) children had
values above (>0.95 mmol/L).Correlates of S-phosphate and S-magnesium at admission
Correlates of S-phosphate and S-magnesium are pre-
sented in Table 2. At admission S-phosphate was posi-
tively associated with S-magnesium (data not shown) and
both were strongly positively correlated with S-albumin
(0.02, 95 % CI: 0.01; 0.03 mmol/L, P < 0.001 and 0.02,
95 % CI: 0.01; 0.02 mmol/L, P < 0.001, respectively). The
mean differences in S-phosphate (−0.13, 95 % CI: −0.31;
0.05 mmol/L) and S-magnesium (−0.12, 95 % CI: −0.24;
0.01 mmol/L) were not significant between edematous
and non-edematous children.S-phosphate and S-magnesium concentrations at
admission by stabilization diet
Age- and sex-adjusted mean S-phosphate at start of
treatment was higher in children admitted during the
national shortage of F-75 (i.e. fed diluted F-100 during
stabilization) compared to those fed F-75 (1.13 vs
0.95 mmol/L, P = 0.03) as was adjusted mean S-
magnesium (1.08 vs 0.94 mmol/L, P = 0.01). The differ-
ences in S-phosphate and S-magnesium persisted after
adjustment for pneumonia (data not shown).
Changes during treatment
Mean S-phosphate increased by 0.49 (95 % CI: 0.39;
0.60) mmol/L and S-magnesium by 0.21 (95 % CI: 0.14;
0.27) mmol/L during treatment (Fig. 2). At start of re-
habilitation phase, S-phosphate in children stabilized
with diluted F-100 was not different from children fed
F-75 (Estimated mean difference: 0.13 (95 % CI: −0.02;
0.28) mmol/L, P = 0.099). There was no difference in S-
phosphate at discharge between children receiving F-75
and diluted F-100 (P = 0.47). The higher S-magnesium
observed at admission in children stabilized with diluted
F-100 persisted at the start of the rehabilitation phase
(estimated mean difference: 0.14 (95 % CI: 0.03; 0.24)
mmol/L, P = 0.01) but at discharge S- magnesium was
not different between children initially stabilized on F-75
and diluted F-100 (Fig. 3). The p-values for diet-time in-
teractions were 0.046 and 0.056 for S-phosphate and S-
magnesium, respectively.
Table 2 Correlates of serum phosphate and magnesium at admission in 72 children with severe acute malnutritiona
[N] S-phosphate, mmol/L S-magnesium, mmol/L
B (95 % CI) P B (95 % CI) P
Female sex [68] 0.10 (−0.06; 0.27) 0.21 0.03 (−0.08; 0.14) 0.63
Age, months [68]
6–24 [29] −0.15 (−0.34; 0.03) 0.10 −0.03 (−0.16; 0.10) 0.63
25–36 [22] ref. ref.
37–60 [17] −0.27 (−0.48; −0.06) 0.01 −0.14 (−0.28; 0.01) 0.07
Edema [68] −0.13 (−0.31; 0.05) 0.16 −0.12 (−0.24; 0.01) 0.07
Anthropometric data
Mid-upper arm circumference, cm [58] 0.01 (−0.04; 0.06) 0.74 −0.01 (−0.05; 0.02) 0.51
Weight-for-height, z [67] −0.02 (−0.07; 0.04) 0.51 −0.02 (−0.06; 0.02) 0.27
Height-for-age, z [68] −0.02 (−0.06; 0.02) 0.37 −0.02 (−0.05; 0.01) 0.12
Serum biochemistry:
Serum alpha-1-Acid glucoprotein, g/L [55] −0.01 (−0.11; 0.10) 0.92 −0.02 (−0.09; 0.05) 0.54
Serum albumin, g/L [68] 0.02 (0.01; 0.03) <0.001 0.02 (0.01; 0.02) <0.001
Co-diagnoses:
Pneumonia [68] −0.07 (−0.25; 0.11) 0.46 −0.03 (−0.16; 0.09) 0.60
Tuberculosis [68] −0.10 (−0.58; 0.37) 0.66 0.20 (−0.12; 0.53) 0.22
One or more co-diagnoses b [68] −0.05 (−0.22; 0.12) 0.58 −0.01 (−0.13; 0.11) 0.85
a Data are regression coefficients B and 95 % confidence intervals adjusted for age and sex
b Co-diagnoses included HIV, tuberculosis, persistent diarrhea and pneumonia
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discharge
At discharge, 18 (51 %) children had S-phosphate below
normal range for children, and 3 (9 %) had S-phosphate
above. Most of the children (29 (83 %)) had S-
magnesium above normal range for children.
Discussion
We found that S-phosphate was low at admission
among children with SAM, consistent with what others
have reported [1, 2, 5, 21, 22]. S-magnesium was above
normal range in the majority of the children at admis-
sion, although there was a large variation which is in ac-
cordance with previous reports [23]. Some studies have
reported normal S-magnesium in the presence of mag-
nesium deficits (indicated by low levels of magnesium in
muscle tissue and low urinary excretion of magnesium)
in children with SAM [24, 25], whereas one study found
low S-magnesium in severely malnourished children
with history of diarrhoea [3]. S-magnesium could be
falsely increased due to mild haemolysis of blood sam-
ples; however, the degree of haemolysis was highest in
blood samples collected at admission, where magnesium
levels were lowest.
Both S-phosphate and S-magnesium correlated posi-
tively with S-albumin. The correlation of S-phosphate
and S-magnesium with S-albumin is in accordance withsome studies [26, 27], but in contrast to other studies
[1, 2]. The correlation might be explained by the fact
that phosphate and magnesium in serum are partially
bound to albumin, or because the same factors caus-
ing low albumin in children with SAM also cause low
S-phosphate and S-magnesium.
Changes during treatment
We observed a steady increase in S-phosphate and S-
magnesium during treatment, both among children with
edematous and non-edematous malnutrition. For S-
phosphate, however, 51 % of children still had levels
below normal on discharge. This might be problematic
for further catch up, as local diets are low in bioavailable
phosphorus. The large number of children lost to
follow-up, however, did not allow us to further explore
predictors of S-phosphate at discharge.
The overall increase in S-phosphate and S-magnesium
are reassuring; however, it is still unknown whether a
higher content of particularly phosphorus would result
in a faster normalization of S-phosphate, and whether
this would improve outcome in terms of growth or mor-
tality. While many children at discharge still have sub-
normal serum concentrations of phosphate, magnesium
concentrations seem to be successfully corrected in most
children, and perhaps even over-corrected. The import-
ance of supplementing malnourished children with
Fig. 2 Estimated mean serum phosphate (a) and serum magnesium
(b) concentrations during treatment in 66 children with severe acute
malnutrition, shown with 95 % confidence intervals
Fig. 3 Estimated mean serum phosphate (a) and serum magnesium
(b) concentrations during treatment, by diet fed during stabilization
phase (F-75 (triangle, n = 41); diluted F-100 (circle, n = 25)) shown
with 95 % confidence intervals, adjusted for sex and age and edema
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its importance to lean tissue accretion, as well as for
homeostasis of K, Ca and other nutrients, and therefore
F-75 and F-100 are fortified with high levels of Mg [17].
However, it is unknown whether the high concentration
observed represents a true surplus of magnesium in the
diet. The finding does however not support that the level
of magnesium in F-100 should be the limiting nutrient
for growth, as suggested [17].
Ideally, evaluation of the adequacy of current magne-
sium and phosphorus content of F-75 and F-100 wouldrequire a trial of nutritional products with different
levels, and with measurement of urinary excretion and
growth. It would also have been desirable to have mea-
sured S-phosphate on day two, to assess whether the
currently used diets are able to prevent the previously
described phosphate nadir after starting refeeding.
Feeding diluted F-100 compared to F-75
Ideally, blood samples should have been taken before the
first feed was given, but in practice this was almost
Hother et al. BMC Pediatrics  (2016) 16:178 Page 8 of 9impossible as initiation of treatment had highest priority
and routine management does not include blood sam-
pling. All blood samples were taken within the first 24 h
after, but after the first feed was given. It is thus possible
that the higher admission levels of S-phosphate and S-
magnesium in children stabilized using F-100 could be
caused by the diet. In support of this, previous studies
have found that changes in S-phosphate during the first
days of treatment depend on the type of diet given and
that a phosphate nadir may occur during the first couple
of days of treatment [1, 2]. The higher S-phosphate con-
centration at admission in children fed diluted F-100 is
however somewhat surprising, as diluted F-100 contains
less phosphorus than F-75. Acute infections have been
associated with hypophosphatemia [28], but we did not
find that the higher proportion of pneumonia among
children fed F-75 could explain the lower S-phosphate.
Another possible explanation could be that diluted F-
100 provides less energy derived from carbohydrate and
more from fat, possibly blunting the insulin response to
refeeding, causing less flux of phosphate into the cells.
Furthermore, the main source of phosphorus in F-100 is
milk, which may be better absorbed than the inorganic
phosphate salts with which F-75 is fortified. The study
was not randomized to assess the effect of diluted F-100,
and therefore our results should be interpreted with cau-
tion, and ideally re-tested in other settings.
Strengths and limitations
This is one of the first studies to describe the pattern
of P-phosphate in children with SAM receiving stand-
ard pre-mixed F-75 and F-100 fortified with phos-
phorus. A number of limitations pertain to the
presented data. First, the observational design pre-
cludes conclusions about causality. Second, with the
modest sample size, the power to detect differences
was limited. Furthermore, it proved very difficult to
get frequent blood samples in the first few days, as
originally planned, so the second blood sample was
postponed until the end of transition phase where the
children were stable. Furthermore, it would have been
ideal to take the first blood sample before the first
feed, to be able to describe the acute effect of initi-
ation of treatment. Finally, blood sampling was not
complete and loss to follow-up was considerable
which could introduce selection bias.
Conclusion
Hypophosphatemia was common among children with
SAM at admission, and still subnormal in about half of
the children at discharge. This could be problematic for
further recovery as phosphorus is needed for catch-up
growth and local diets are likely to be low in bioavailable
phosphorus. The high S-magnesium levels at dischargedoes not support that magnesium should be the limiting
nutrient for growth in the F-100 diet. Although diluted
F-100 (75 kcal/100 mL) is not designed for stabilizing
children with SAM, it did not seem to cause lower S-
phosphate than in children fed F-75.
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